RxDoctor Payments Data

William Sciortino, MD

Ophthalmology · Saint Louis, MONPI 1831202274

Payments from drug & device makers

$3,409in general payments, 2019–2025

Across 84 payments — averaging $40.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$465
  • Novartis$346
  • Amgen$225
  • Aerie Pharmaceuticals, Inc.$156
  • Sun Pharmaceutical Industries Inc.$152
  • plus $474 from 9 others

What the payments were for

  • Travel & lodging$65319%
  • Food & beverage$2,75681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,409 in reported general payments places this provider in the 60th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$37,119
Medicare patients
217
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost60$30,608
XiidraLifitegrast19$18,621
Cyclosporine39$17,941
RestasisCyclosporine14$9,533
RhopressaNetarsudil Mesylate20$8,407
Brimonidine Tartrate107$6,804
Travoprost38$6,143
Alphagan PBrimonidine Tartrate13$5,734
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$5,377
Latanoprost697$5,309
CombiganBrimonidine Tartrate/Timolol11$4,338
RocklatanNetarsudil Mesylat/Latanoprost11$3,681
Prednisolone Acetate127$3,356
Timolol Maleate92$1,507
Ciprofloxacin Hcl106$1,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$465$50,21398 claims
Bausch & Lomb Americas Inc.Xiidra$121$18,62119 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$156$12,08831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →